In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors.

[1]  E. Sausville,et al.  Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[2]  K. Keshari,et al.  High-Throughput Indirect Quantitation of 13C Enriched Metabolites Using 1H NMR. , 2016, Analytical chemistry.

[3]  S. de Botton,et al.  IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives , 2016, Journal of blood medicine.

[4]  Shery Jacob,et al.  A simple practice guide for dose conversion between animals and human , 2016, Journal of basic and clinical pharmacy.

[5]  A. Iafrate,et al.  Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. , 2015, Cancer cell.

[6]  K. Keshari,et al.  13C-labeled biochemical probes for the study of cancer metabolism with dynamic nuclear polarization-enhanced magnetic resonance imaging , 2015, Cancer & Metabolism.

[7]  Christian M. Metallo,et al.  Metabolic consequences of oncogenic IDH mutations. , 2015, Pharmacology & therapeutics.

[8]  Eyal Gottlieb,et al.  Oncometabolites: tailoring our genes , 2015, The FEBS journal.

[9]  C. Brennan,et al.  Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo , 2015, Science Translational Medicine.

[10]  Se-Hoon Lee,et al.  Metabolomic comparison between cells over‐expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism , 2015, Journal of neurochemistry.

[11]  Sunit Das,et al.  IDH mutation in glioma: new insights and promises for the future. , 2014, JAMA neurology.

[12]  J. L. Izquierdo-García,et al.  Glioma Cells with the IDH1 Mutation Modulate Metabolic Fractional Flux through Pyruvate Carboxylase , 2014, PloS one.

[13]  Christian M. Metallo,et al.  IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. , 2014, Cancer research.

[14]  T. Soga,et al.  Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation , 2014, Tumor Biology.

[15]  David M. Wilson,et al.  Chemistry and biochemistry of 13C hyperpolarized magnetic resonance using dynamic nuclear polarization. , 2014, Chemical Society reviews.

[16]  Matthew G. Vander Heiden,et al.  Metabolic targets for cancer therapy , 2013, Nature Reviews Drug Discovery.

[17]  Matthew G. Vander Heiden,et al.  Metabolic targets for cancer therapy , 2013, Nature Reviews Drug Discovery.

[18]  Daniel B Vigneron,et al.  Non-invasive in vivo assessment of IDH1 mutational status in glioma , 2013, Nature Communications.

[19]  B. Rosen,et al.  Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. , 2013, The Journal of clinical investigation.

[20]  Tomoyoshi Soga,et al.  Oncometabolites: linking altered metabolism with cancer. , 2013, The Journal of clinical investigation.

[21]  P. Larson,et al.  Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate , 2013, Science Translational Medicine.

[22]  L. Venturi,et al.  In vivo and in vitro liver cancer metabolism observed with hyperpolarized [5-(13)C]glutamine. , 2013, Journal of magnetic resonance.

[23]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[24]  W. Kaelin,et al.  What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. , 2013, Genes & development.

[25]  O. Abdel-Wahab,et al.  The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization* , 2012, The Journal of Biological Chemistry.

[26]  A. Iafrate,et al.  Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. , 2012, Blood.

[27]  Dania Daye,et al.  Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. , 2012, Seminars in cell & developmental biology.

[28]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[29]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[30]  Ovidiu C. Andronesi,et al.  Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy , 2012, Science Translational Medicine.

[31]  Dinesh Rakheja,et al.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients , 2011, Nature Medicine.

[32]  Hong Wu,et al.  Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy , 2012, Journal of Neuro-Oncology.

[33]  L. Chodosh,et al.  PET Imaging of Glutaminolysis in Tumors by 18F-(2S,4R)4-Fluoroglutamine , 2011, The Journal of Nuclear Medicine.

[34]  Y. Yen,et al.  Quantification of in vivo metabolic kinetics of hyperpolarized pyruvate in rat kidneys using dynamic 13C MRSI , 2011, NMR in biomedicine.

[35]  H. Kung,et al.  Facile synthesis [5-(13)C-4-(2)H(2)]-L-glutamine for hyperpolarized MRS imaging of cancer cell metabolism. , 2011, Academic radiology.

[36]  K. Kinzler,et al.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.

[37]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[38]  K. Yen,et al.  Cancer-associated IDH mutations: biomarker and therapeutic opportunities , 2010, Oncogene.

[39]  G. Riggins,et al.  Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. , 2010, Cancer research.

[40]  S. Su,et al.  IDH mutations in glioma and acute myeloid leukemia. , 2010, Trends in molecular medicine.

[41]  M. Caligiuri,et al.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[43]  M. J. van den Bent,et al.  IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide , 2009, Neurology.

[44]  H. Zentgraf,et al.  Monoclonal antibody specific for IDH1 R132H mutation , 2009, Acta Neuropathologica.

[45]  Anthony Mancuso,et al.  Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.

[46]  Pernille R. Jensen,et al.  Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate , 2008, Nature.

[47]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[48]  E. Gottlieb,et al.  Cell-Permeating α-Ketoglutarate Derivatives Alleviate Pseudohypoxia in Succinate Dehydrogenase-Deficient Cells , 2007, Molecular and Cellular Biology.

[49]  J. Wernerman,et al.  Glutamine kinetics during intravenous glutamine supplementation in ICU patients on continuous renal replacement therapy , 2007, Intensive Care Medicine.

[50]  U. Ungerstedt,et al.  Intravenous glutamine supplementation to head trauma patients leaves cerebral glutamate concentration unaffected , 2006, Intensive Care Medicine.

[51]  Wolfgang A Weber,et al.  Use of PET for monitoring cancer therapy and for predicting outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.